Biomarkers in obstructive respiratory diseases: An update

Panminerva Medica

Volumn 54, Issue 2, 2012, Pages 119-127

  Braido, F ^a   Bagnasco, D ^a   Scichilone, N ^b   Santus, P ^c   Solidoro, P ^d   Di Marco, F ^c   Corsico, A ^e   Canonica, G W ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d MOLINETTE HOSPITAL   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

Author keywords

Biomarkers; Chronic obstructive; Outcome assessment; Pulmonary disease

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; UTEROGLOBIN;

CHEMISTRY; CHRONIC OBSTRUCTIVE LUNG DISEASE; FORCED EXPIRATORY VOLUME; HUMAN; METABOLISM; PATHOPHYSIOLOGY; REVIEW; SPUTUM;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FORCED EXPIRATORY VOLUME; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM; UTEROGLOBIN;

EID: 84862547838     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. World Health Organization. Global burden of disease [Internet, [cited 2012 April 6]. Available at: www.who.int/topics/global-burden-of-disease
2. De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L et al. Considerations in the evaluation of surrogate endpoints in clinical trials, summary of a National Institutes of Health workshop. Control Clin Trials 2001;22:485-502. (Pubitemid 32907433)
3. Manolio T. Novel risk markers and clinical practice. N Engl J Med 2003;349:1587-9. (Pubitemid 37288564)
4. Sharma G, Hanania NA, Shim YM. The aging immune system and its relationship to the development of chronic obstructive pulmonary disease. Proc AmThorac Soc 2009;6:573-80.
5. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS et al. Chronic obstructive pulmonary disease: Current burden and future projections. Eur Respir J 2006;27:397-412. (Pubitemid 43180921)
6. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-80. (Pubitemid 38901515)
7. Cazzola M, Boveri B, Carlucci P, Santus P, Di Marco F, Centanni S et al. Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT(1)-receptor antagonist. Pulm Pharmacol Ther 2000;13:301-5.
8. Saetta M, Di Stefano A, Turato G, Facchini FM, Corbino L, Mapp CE et al. CD81 T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:822-6.
9. O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD81 T lymphocytes with FEV 1. Am J Respir Crit Care Med 1997;155:852-7. (Pubitemid 27133393)
10. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33:1165-85.
11. Franceschi C, Monti D, Sansoni P, Cossarizza A. The immunology of exceptional individuals: the lesson of centenarians. Immunol Today 1995;16:12-6.
12. O'Kelly N, Robertson W, Smith J, Dexter J, Carroll-Hawkins C, Ghosh S. Short-term outcomes in heart failure patients with chronic obstructive pulmonary disease in the community. World J Cardiol 2012;4:66-71.
13. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E et al. Inflammaging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000;908:244-54.
14. Vasto S, Candore G, Balestrieri CR, Caruso M, Colonna-Romano G, Grimaldi MP et al. Inflammatory networks in ageing, age-related diseases and longevity. Mech Aging Dev 2007;128:83-91. (Pubitemid 46073064)
15. Scichilone N, Marchese R, Catalano F, Togias A, Vignola AM, BelHa V. The bronchodilatory effect of deep inspiration diminishes with aging. Respir Med 2004;98:838-43. (Pubitemid 39069332)
16. De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett 2005; 11;579:2035-9. (Pubitemid 40469666)
17. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010,11:122.
18. Tanino M, Betsuyaku T, Takeyabu K, Tanino Y, Yamaguchi E, Miyamoto K et al. Increased levels of interleukin-8 in BAL fluid from smokers susceptible to pulmonary emphysema. Thorax 2002;57:405-11. (Pubitemid 34494150)
19. Kanazawa H, Asai K, Hirata K, Yoshikawa J. Possible effects of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. Am J Med 2003;114:354-8. (Pubitemid 36513682)
20. Lapperre TS, Willems LN, Timens W, Rabe KF, Hiemstra PS, Postma DS et al. Small airways dysfunction and neutrophilic inflammation in bronchial biopsies and BAL in COPD. Chest 2007; 131:53-9. (Pubitemid 46122974)
21. Rutgers SR, Timens W, Tzanakis N, Kauffman HF, van der Mark TW, Koëter GH et al. Airway inflammation and hyperresponsiveness to adenosine 5'-monophosphate in chronic obstructive pulmonary disease. Clin Exp Allergy 2000;30:657-62. (Pubitemid 30305628)
22. Papi A, Romagnoli M, Baraldo S, Braccioni F, Guzzinati I, Saetta M et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:1773-7.
23. Leigh R, Pizzichini MM, Morris MM, Maltais F, Hargreave FE, Pizzichini E. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006;27:964-71. (Pubitemid 44911110)
24. Karadag F, Kami AB, Cildag O, Yilmaz M, Ozcan H, Biomarkers of systemic inflammation in stable and exacerbation phases of COPD. Lung 2008;186:403-9.
25. Bruunsgaard H. Effect of tumor necrosis factor-alpha and interleukin-6 in elderly populations. Eur Cytokine Netw 2002; 13:38991.
26. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111:1805-12. (Pubitemid 38057722)
27. Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007;175:783-90. (Pubitemid 46631789)
28. Cano NJ, Pichard C, Roth H, Court-Fortuné I, Cynober L, GérardBoncompain M et al. C-reactive protein and body mass index predict outcome in end-stage respiratory failure. Chest 2004; 126:5406.
29. Pinto-Plata VM, Miillerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS et al. C-reactive protein in patients with COPD, control smokers, and no smokers. Thorax 2006;61:23-8. (Pubitemid 43106973)
30. de Torres JP, Cordoba-Lanus E, Lopez-Aguilar C, Muros de Fuentes M, Montejo de Garcini A, Aguirre-Jaime A et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006:902-7. (Pubitemid 44911101)
31. Agusti AGN, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347-60. (Pubitemid 36204553)
32. Gan WQ, Paulman SF, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 2005;127:558-64. (Pubitemid 40229317)
33. Snider GL. Understanding inflammation in chronic obstructive disease: the process begins. Am J Respir Crit Care Med 2003; 167:10456.
34. de Torres JP, Pinto-Plata V, Casanova C, Mullerova H, CórdobaLanús E, Muros de Fuentes M et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008;133:1336-43. (Pubitemid 351892988)
35. Ridker P. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9. (Pubitemid 36158034)
36. Linnemann B, Voigt W, Nobel W, Janka HU. C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome. Exp Clin Endocrinol Diabet 2006; 114:127-34.
37. Racki S, Zaputović L, Mavrić Z, Vujicić B, Dvornik S. C-reactive protein is a strong predictor of mortality in hemodialysis patients. Ren Fail 2006;427-33. (Pubitemid 44049788)
38. Lowe GD, Pepys MB. C-reactive protein and cardiovascular disease: weighing the evidence. Curr Atheroscler Rep 2006;8:421-8. (Pubitemid 44340187)
39. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:867-74. (Pubitemid 44564786)
40. Donaldson G. C-reactive protein: does it predict mortality? Am J Respir Crit Care Med 2006;175:209-10.
41. Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA. Users' guides to the medical literature: XIX. Applying clinical trial results: A. How to use an article measuring the effect of an intervention on surrogate end points: Evidence-Based Medicine Working Group. JAMA 1999;282:771-8. (Pubitemid 29404385)
42. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-69.
43. Man SF, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. -Reactive Protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006;61:849-53. (Pubitemid 44570304)
44. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) Eur Respir J 2008;31:869-73.
45. Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA, Tal-Singer R. Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011;12:146.
46. Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;175:926-34.
47. Braido F, Riccio AM, Guerra L, Gamalero C, Zolezzi A, Tarantini F et al. Clara celilo protein in COPD sputum: a marker of small airways damage? Respir Med 2007; 101:2119-24. (Pubitemid 47324246)
48. Lomas DA, Silverman EK, Edwards LD, Miller BE, Coxson HO, Tal-Singer R. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax 2008;63:1058-63.
49. Santus P, Sola A, Carlucci P, Fumagalli F, Di Gennaro A, Mondoni M et al. Lipid peroxidation and 5-lipoxygenase activity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:838-43. (Pubitemid 40562714)
50. Lomas DA, Silverman EK, Edwards LD, Locantore NW, Miller BE, Horstman DH et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study investigators. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009;34:95-102.
51. Foreman MG, Kong X, DeMeo DL, Pillai SG, Hersh CP, Bakke P et al. Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2011;44:316-22.
52. Singh D, Edwards L, Tal-Singer R, Rennard S. Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res 2010;11:77.
53. Casado B, Iadarola P, Pannell LK, Luisetti M, Corsico A, Ansaldo E el al. Protein expression in sputum of smokers and chronic obstructive pulmonary disease patients: a pilot study by CapLC-ESIQ-TOF. J Proteome Res 2007;6:4615-23.
54. MacNee W, Rennard SI, Hunt JF, Edwards LD, Miller BE, Locantore NW et al. Evaluation of exhaled breath condensate pH as a biomarker for COPD. Respir Med 2011; 105:1037-45.
55. Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P et al. Inflammatory biomarkers improve clinical prediction of mortal ity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012 [E-pub ahead of print].
56. Braido F, Baiardini I, Balestracci S, Menoni S, Balbi F, Ferraioli G et al. Chronic obstructive pulmonary disease patient well-being and its relationship with clinical and patient-reported outcomes: a reallife observational study. Respiration 2011;82:335-40.
57. Braido F, Baiardini I, Menoni S, Bagnasco AM, Balbi F et al. Disability in COPD and its relationship to clinical and patient-reported outcomes. Curr Med Res Opin 2011;27:981-6.
58. Holgate ST. Pathophysiology of asthma: what has our current understanding taught us about new therapeutic approaches?J Allergy Clin Immunol 2011;128:495-505.
59. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;22:1088-98.
60. Bateman DE, Boushey HA, Bousquet J, Busse WW, Clark TJ et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med 2004;170:836-44. (Pubitemid 39346477)
61. Braido F, Baiardini I, Balestracci S, Ghiglione V, Stagi E, Ridolo E et al. Does asthma control correlate with quality of life related to upper and lower airways? A real life study. Allergy 2009;64:937-43.